Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
Toggle Summary Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced certain corporate changes to
Toggle Summary Seres Therapeutics Announces Chief Executive Officer Transition
- Eric Shaff , previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz , M.D., to continue to serve as Chairman - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc .
Toggle Summary Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc .
Toggle Summary Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 th at 9:30 a.m. ET . A live audio webcast of the presentation will be available under the
Toggle Summary Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Kevin Horgan , M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b
Toggle Summary Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.
Toggle Summary Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Dr. Horgan, an immunology and oncology drug development expert, is well positioned to drive Seres microbiome clinical programs forward CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Kevin Horgan , M.D., as Executive
Toggle Summary Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced it will present new data for SER-109, a microbiome candidate in Phase 3 development, at
Toggle Summary Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2018-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced the appointment of Meryl Zausner , a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the

Back to top